Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients  by Fluge, G. et al.
(2009) 198–202
www.elsevier.com/locate/jcfJournal of Cystic Fibrosis 8Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic
fibrosis patients
G. Fluge a,⁎, H.V. Olesen b, M. Gilljam c, P. Meyer d, T. Pressler e, O.T. Storrösten f,
F. Karpati g, L. Hjelte g
a Department of Pediatrics, Haukeland Univ. Hospital, Bergen, Norway
b Pediatric Department, Aarhus University Hospital Skejby, Aarhus, Denmark
c West Swedish CF Center and Sahlgrenska University Hospital, Gothenburg, Sweden
d Pediatric Department, Lund University Hospital, Lund, Sweden
e Copenhagen CF Center, Rikshospitalet, Copenhagen, Denmark
f National Centre For Cystic Fibrosis, Ullevaal University Hospital, Oslo, Norway
g Stockholm CF Centre, Karolinska University Hospital Huddinge, Stockholm, Sweden
Received 21 August 2008; received in revised form 9 February 2009; accepted 26 February 2009
Available online 19 March 2009Abstract
Background: The co-morbidity of cystic fibrosis (CF) and celiac disease (CD) has been reported sporadically since the 1960s. To our knowledge,
this is the first time a systematic screening is performed in a large cohort of CF patients.
Methods: Transglutaminase-IgA (TGA), endomysium-IgA (EMA) and total IgA in serum were measured in 790 CF patients (48% females, 86%
with pancreatic insufficiency). Six patients were diagnosed with CD prior to the study, all receiving a gluten-free diet.
Patients with elevated TGA (N50 Units/mL) and a positive EMA test were offered a gastroscopy obtaining mucosal biopsies from the
duodenum.
Results: Four new cases of CD were diagnosed. Two additional patients had positive serological tests, but normal biopsies.
In total, 10 cases of CD (1.2%, 1:83) indicate a prevalence rate about three times higher than the general prevalence of CD in Norway and
Sweden. No CD patients were detected in the Danish CF cohort.
Patients diagnosed with untreated CD reported symptoms typical of both CF and CD (poor weight gain, loose and/or fatty stools, fatigue,
irritability, abdominal pain). They improved after introduction of a gluten-free diet.
Conclusions: Systematic screening for CD in a Scandinavian cohort of CF patients revealed a higher prevalence of CD than in the general
population. Clinical signs of CD are difficult to differentiate from CF with malabsorption, and patients may go undiagnosed for a long time. In a
population where CD is common we recommend screening for CD in patients with CF.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Celiac disease; Co-morbidity; Prevalence1. Introduction
Celiac disease (CD) is common in Caucasians with
prevalence rates ranging from 1:300 to 1:200 in most
publications [1–8]. A high prevalence was recently reported
in Finland (1:100) after serological screening and duodenal⁎ Corresponding author.Hesjakollen 104N-5142Fyllingsdalen,Norway. Tel.: +47
55168107; fax: +47 55975147.
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doi:10.1016/j.jcf.2009.02.002biopsies whenever blood tests were positive [9]. The diagnosis
must be confirmed by duodenal biopsies showing villous
flattening and increased numbers of intraepithelial lymphocytes
and ideally, control biopsies should be taken after introduction
of gluten-free diet and also after provocation with gluten [10].
Serological tests include transglutaminase-IgA (TGA) and
endomysium-IgA (EMA).
Since both CD and cystic fibrosis (CF) cause intestinal
malabsorption in the majority of cases, it is difficult to identify
patients having CD in the CF population. Sporadic case reportsd by Elsevier B.V. All rights reserved.
Table 1
Patients with both cystic fibrosis (CF) and celiac disease (CD).
Patient
number
Poor
weight
gain
Loose
stools
Fatty
stools
Meteorism Abdominal
pain
Fatigue Irritability
1 Yes Yes Yes Yes Yes Yes No
2 Yes Yes Yes – – – –
3 Yes Yes – – – – –
4 Yes Yes – – – – –
5 Yes – – – – – –
6 Yes Yes Yes Yes No Yes No
7 No Yes Yes Yes Yes Yes Yes
8⁎ No No No No Yes No No
9 No Yes No Yes Yes Yes Yes
10 No Yes Yes No Yes No No
Clinical symptoms at diagnosis of CD.
Bold: newly diagnosed patients (screened). ⁎=Type 1 diabetes.
Table 2
Patients with both cystic fibrosis and celiac disease.
Patient
number
Sex Age at
diagnosis,
CF, years
Age at
diagnosis,
CD, years
Age
at study
years
Pancreatic
insufficiency
Height
percentile
Weight
percentile
1 F 1.8 1.8 6.1 Yes 25 b2.5
2 M 0.1 1.0 16.6 Yes 2.5 50
3 F 0.8 0.5 8.0 Yes 10 10
4 F 1.4 0.7 18.5 Yes b2.5 2.5
5 F 2.2 1.0 18.1 Yes 50 10
6 M 0.7 0.7 8.4 Yes 25 b2.5
7 M 0.4 2.4 2.4 Yes 2.5 50
8⁎ F 0.6 6.9 6.9 Yes 10 97.5
9 M 0.3 26.7 26.7 Yes 75 90
10 F 3.7 8.7 8.7 Yes 75 2.5
Clinical data at diagnosis of CD.
Bold: newly diagnosed patients (screened). ⁎=Type 1 diabetes
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The chance of the two conditions to occur in the same patient
has been calculated to be 1 in 2,000,000–1:5,900,000 [11,12].
The prevalence of CD among 1100 CF patients in an Italian CF
clinic was 1:220 [13]. In 1999 15 cases were collected from the
literature, and one further patient was reported by the authors
[14]. Since 2000, three papers have been published [15–17],
reporting co-morbidity of CF and CD. To our knowledge, there
has been no systematic screening reported for CD among CF
patients.
2. Materials and methods
A cross-sectional, multi-centre study of the nutritional status
in Scandinavian CF patients was conducted by the Scandina-
vian CF Study Consortium (SCFSC) in 2004–05. Six CF
Centres from Denmark, Norway and Sweden participated. As
part of the study, screening for celiac disease was performed
with analyses of TGA and EMA in serum, and total s-IgA was
included in order to identify patients with IgA deficiency.
Furthermore, s-iron, s-ferritin, 25-OH-vitamin D, vitamin A and
E were measured. Samples from patients with IgA deficiency
were reanalyzed with IgG antibodies. Height and weight were
expressed in percentiles.
There were 790 patients (age above six months) included in
this part of the study. 107 of totally 898 patients in the main
study were excluded because analysis of either TGA, EMA or
both had not been performed, and one patient was excluded
because of low age (3 months). Age at the time of study ranged
from 2.7 to 64.6 years. Forty-eight % of patients were females,
and 86% received pancreatic enzymes for pancreatic exocrine
insufficiency (PI).
TGA, EMA and IgA were analysed at The Research
Laboratory, Department of Pediatrics, Haukeland University
Hospital, Bergen, Norway (head: Prof. L. Aksnes). TGA was
measured by ELISA technique (Anti-huTransG, Generic
Assays GmbH, D1527 Dahlowitz, Germany). Levels above
50 Units/mL were considered elevated. Anti-endomysium IgA
antibodies were determined by an immunofluorescens method
using monkey oesophagus (BioSystems SA, Barcelona, Spain)as substrate as described by Unsworth [18]. Sera were diluted 1/
5 in PBS, and the antigen–antibody was determined by FITC-
conjugated anti-human IgA (Inova Diagnostics Inc, CA, USA).
Results are given as positive or negative.
In cases of IgA deficiency, IgG antibodies against human
transglutaminase and deamidated gliadin were measured
(Quanta Lite Gliadin IgG II, Inova Diagnostics INC, San
Diego CA92131, USA).
Patients with both elevated TGA (N50 Units/mL) and a
positive EMA test were offered a gastroscopy obtaining
mucosal biopsies from the duodenum, performed at a local
gastroenterology unit. Histological examination was carried out
by experienced pathologists, and findings were reported as
normal or pathological (fulfilling the criteria of CD). Symptoms
in the untreated state in previously diagnosed and new patients
with CD were reported in a questionnaire. Patients with positive
TGA but negative EMA were assessed for symptoms and
repeated serological tests were advised.
3. Results
Six patients were already diagnosed with CD at inclusion.
Among the 790 patients tested for CD, six had elevated TGA
and a positive EMA test. Duodenal biopsies were pathologic,
compatible with the diagnosis of CD, in four of these and
normal in the remaining two. In our patient cohort, ten patients
were thus recorded as having both CF and CD (1.2%, 1:83
individuals). The CD diagnosis was made prior to the CF
diagnosis in three cases, and simultaneously in two cases.
Seventeen patients had total IgA levels below 0.2 g/L, and in
three IgAwas undetectable. Anti-gliadin IgG and TG-IgG were
elevated in two of these patients. TGA and EMA were also
positive in one of them (total IgA 0.1 g/L), and duodenal
biopsies verified the diagnosis of CD (patient no 7, see
Tables 1–3). The other patient probably also has CD and will be
followed-up accordingly.
Elevated TGA (55–226 Units/mL) and a negative EMA test
were found in 13 patients. CD was not suspected in these cases.
These patients had height and weight within the normal age
limits and had no symptoms. Likewise, iron- and fat-soluble
Table 3
Patients with both cystic fibrosis (CF) and celiac disease (CD).
Patient
number
CF genotype TGA, U/mL
(b50)
Endomysium S-iron, µmol/L
(11–29)
S-ferritin µg/L
(10–160)
25-OH-Vit. D, nmol/L
(30–130)
Vit. A µmol/L
(N0.7)
Vit. E µmol/L
(N11.6)
FEV–1% of
predicted
1 Unknown 6.4 Neg 18.4 17 95.2 1.8 28 92
2 F508del/F508del 10 Neg 12.0 49 31.8 0.8 14.4 38
3 F508del/3659delC 0.8 Neg 13.0 7⁎⁎ 41.9 1.4 26.6 96
4 394delTT/394delTT 3.8 Neg 15.0 100 60.8 1.7 23.1 117
5 F508del/F508del 7.9 Neg 10.0 7⁎⁎ 22.1⁎⁎ 0.9 1.1⁎⁎ 54
6 F508del/394delTT 20.3 Neg 14.0 106 48.9 1.5 27.7 89
7 F508del/3659delC 82.0 Pos 15.0 16 42.5 1.8 31.1 –
8⁎ F508del/F508del 349.0 Pos 14.0 27 64.5 1.1 25.0 88
9 F508del/F508del 597.3 Pos 14.7 19 45.3 1.2 5.0⁎⁎ 85
10 394delTT/1525-
2A-G
213.2 Pos 20.9 14 13.7⁎⁎ 0.7⁎⁎ 17.4 80
Laboratory data at the time of study.
Bold: newly diagnosed patients (screened). ⁎=Type 1 diabetes , ⁎⁎=reduced serum value (normal values in parentheses).
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quently, no biopsies were performed.
The TGA levels in the total CF cohort varied between 0 and
597 Units/mL, mean 12.3 and SD 32.8.
Symptoms encountered at diagnosis in the celiac patients
were: poor weight gain, loose and or fatty stools, fatigue,
irritability, abdominal pain and meteorism. One patient had
dental enamel dysplasia (patient no 9). Clinical symptoms and
some clinical data at diagnosis of CD are presented in Tables 1
and 2. One patient had type 1 diabetes mellitus. Laboratory data
at the time of study in both previously diagnosed and newly
diagnosed patients after screening are shown in Table 3. All 10
patients had exocrine pancreatic insufficiency. The six pre-
viously diagnosed CD patients had normal EMA and TGA tests
at study.
At the time of study, reduced levels of vitamin D were found
in two patients, low Vit. A in one, and reduced Vit. E in two
patients, equally distributed among newly diagnosed CD
patients and those treated with a gluten-free diet. Reduced
levels of fat-soluble vitamins were often encountered also in the
entire (non-celiac) CF cohort (Vit. D 18%, Vit. E 12% and Vit.
A 4%. Two treated CD patients had reduced ferritin levels.
Among the 10 patients with CD, mutation F508del was found
in seven patients, homozygous in four. The 394delTT mutation
was detected in three patients, homozygous in one of them.
FEV1 was used as a measure of their general CF condition at
the time of the main study. Median FEV1 was 88% predicted in
the celiac patients (range 38–117%, median age 8.5 years) versus
82% (range 16–137, median age 18.5 years) in the non-celiacs.
4. Discussion
We report a high prevalence of 1.2% (1:83) of celiac disease
among Scandinavian cystic fibrosis patients.
The observed prevalence is equal to or higher than the highest
prevalence reported in the general population from the Nordic
countries. These figures can not be compared to the calculated risk
of the co-morbidity of CF and CD, suggested by Goodchild and
Taylor [11,12], since their risk figureswere based on the occurrence
of co-morbidity of both diseases in the general population.Screening of healthy blood donors in Norway and popula-
tion-based studies from Sweden revealed prevalence rates of
1:340 [1] and 1:189, respectively [2]. In Denmark, prevalence
rates around 1:10,000 have been reported from paediatric
studies [19,20]. However, serological studies among 1573
Danish blood donors indicated a prevalence of 1:394. Still, no
biopsies were taken from these individuals. Simultaneously,
1866 Swedish blood donors were investigated, and biopsy-
proven CD was diagnosed in five (1:373) individuals [4]. The
prevalence of CD seems to have increased over time [6]. In
Finland, the prevalence has increased from 1.05% in 1978–80
to 1.99% in 2000–01 [9].
There were no patients with CD in the Danish CF cohort.
This may reflect the low prevalence rates reported from
Denmark [21]. Three patients with CD were Norwegian, the
remaining seven were Swedish, five of whom from the Swedish
west coast. This probably reflects that CD is more common in
this area than in the rest of Sweden [22].
The expected prevalence can be calculated from the
prevalence in the general population and the number of CF
patients studied. In Norway the expected number of patients
with CD in the CF cohort would be 1:340×179=0.53. For
Sweden, we have based our estimate on a general prevalence
rate of 1:189 and 426 patients, which gives an expected number
of 2.2 patients. We have no solid prevalence data for CD in the
Danish population. Based on serological data (no biopsies) [7]
we have calculated the expected number of Danish patients with
CD to be 1:394×236=0.6. Using other prevalence rates,
indicating that CD is very rare in Denmark [19,20], we would
have a much lower number of expected CD patients in the
Danish CF population (0.02). The registered number of patients
having celiac disease among Scandinavian cystic fibrosis
patients are thus estimated to be 2 to 3 times higher than in
the general population, when based on prevalence rates from
several studies.
In addition to the four newly diagnosed patients with CD,
two had positive serological tests, but normal histological
findings in their duodenal biopsies. This may indicate that they
could later develop CD, and should be followed up accordingly.
Patients with IgA deficiency were tested with IgG gliadin and
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tests based on IgA may fail to identify patients with celiac
disease. There may be one additional celiac patient in this
category. Duodenal biopsies are still to be taken in this patient.
In 13 patients, elevated transglutaminase-IgA and a negative
endomysium test were found. There were no clinical indications
of CD, and no biopsies were taken. In three of these patients TGA
levels were above 100 Units/mL. Such high levels are associated
with villous atrophy (Marsh 3 histopathology in duodenal
biopsies) [23]. It may be argued that biopsies should have been
taken in these three patients in spite of a negative EMA test. The
decisions whether biopsies should be taken or not were made at
the CF units in charge, and were not part of the study protocol.
However, the CF units have been advised to follow-up these
patients taking new serological tests after a few years.
TGA is a sensitive screening test [24–26]. IgA antibodies
against both transglutaminase and endomysium correlate
significantly with histological findings [23]. A rapid test for
TGA in a screening of Finnish children had a sensitivity of 78%,
and a specificity of 100% for a final diagnosis of CD [27]. We
found no general trend towards elevated TGA in the CF cohort.
About half of the celiac patients had typical symptoms of the
disease. Poor weight gain and loose stools were most frequently
reported. In five cases the CD diagnosis was made before or at
the same time as the CF diagnosis. It would be difficult to
differentiate between these two conditions on clinical grounds,
and reduced levels of iron and fat-soluble vitamins are equally
distributed among celiac and non-celiac individuals.
In CF patients, celiac disease may go undiagnosed for a long
time, despite typical symptoms. Both in our experience and
from the literature, these patients appear to benefit from a
gluten-free diet, ameliorating the component of malabsorption
in their clinical condition, and improving their symptoms.
Moreover, the chronic intestinal inflammation in celiac disease
is associated with an increased risk of osteoporosis [28] and
intestinal cancer [29], stressing the importance of an early
diagnosis. In a population with a high prevalence of CD, such as
Sweden, we suggest that screening should be undertaken at
diagnosis of CF in patients older than nine months or about
three months after gluten has been introduced in the diet.
In our opinion, the co-morbidity of CF and CD is more than a
mere coincidence, although it may be argued that it could just
reflect the very high prevalence of CD having been reported
lately from Finland and Sweden [8,9].
Various explanations for the co-morbidity have been
presented, from mere coincidence to a heavy burden of
undigested gluten proteins in the intestine due to exocrine
pancreatic insufficiency, and intestinal mucosal damage due to
malnutrition and an immunological response against wheat
gluten [17].
No pre-disposition to CD relating to specific CF mutations
was found, except a small over-representation of the 394delTT
mutation (3/10 patients). It is likely that our CF patients with co-
existing CD carry the genetic disposition for CD without any
connection to their CF mutations.
In conclusion, systematic screening in a Scandinavian cohort
of CF patients revealed a high prevalence of CD. These twoconditions co-exist more often than it should be expected from
the prevalence rates of CD in the general population. Clinical
symptoms and signs of CD are difficult to differentiate from CF
with malabsorption, and we therefore suggest that serological
screening for CD should be included in the diagnostic work-up
of CF patients older than nine months and in patients with
persistent gastrointestinal symptoms. In a population with a high
prevalence of CD, follow-up screening should be considered.Acknowledgements
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